"Great opportunities" in £2.2 billion UK pathology sector
This article was originally published in Clinica
The reprovisioning of UK National Health Service pathology will offer "the most exciting new opportunities for private and public sector pathology laboratories in the next few years". This is the conclusion of a new report, UK Pathology Markets 2002, from healthcare analysts Laing & Buisson. It maintains that while some change will involve the re-organisation of NHS laboratories, there will also be many opportunities for private-public partnerships with UK and foreign laboratory operators or other pathology-related businesses.
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.